Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea
Status:
Completed
Trial end date:
2020-08-04
Target enrollment:
Participant gender:
Summary
To evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Zydus Worldwide
DMCC) and Soolantra® (ivermectin) cream, 1% (Galderma Laboratories, L.P.) in the treatment of
moderate to severe facial papulopustular rosacea.
To demonstrate the superiority of the efficacy of the test and reference products over that
of the placebo control in the treatment of moderate to severe facial rosacea.